<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the child with metabolic acidosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the child with metabolic acidosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the child with metabolic acidosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Yorgin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Mak, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3666407553"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Metabolic acidosis is a biochemical abnormality defined by an increase in blood hydrogen ion (H<sup>+</sup>) concentration or a reduction in serum bicarbonate (HCO<sub>3</sub>) concentration. It is either an acute or chronic process and is secondary to a wide range of underlying disorders.</p><p>The etiology, clinical impact, and diagnostic evaluation of children with metabolic acidosis will be reviewed. Metabolic acidosis in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis"</a>.)</p><p class="headingAnchor" id="H1275529877"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic acidosis</strong> is defined as a pathologic process that increases the concentration of hydrogen ions (H<sup>+</sup>) and reduces blood bicarbonate (HCO<sub>3</sub>) concentration. It can be acute (minutes to days) or chronic (weeks to months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory acidosis</strong> is defined as an elevation in arterial partial pressure of carbon dioxide (CO<sub>2</sub>) concentration that reduces arterial pH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acidemia</strong> (as opposed to acidosis) is defined as a low arterial pH (&lt;7.35), which can result from a metabolic acidosis, respiratory acidosis, or a combination of both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total CO</strong><strong><sub>2</sub></strong> measured in the electrolyte panel includes measurements of serum HCO<sub>3</sub> (95 percent of total CO<sub>2</sub>), dissolved CO<sub>2</sub>, and carbonic acid.</p><p></p><p class="headingAnchor" id="H2336567861"><span class="h1">ETIOLOGY BASED ON PATHOGENESIS</span></p><p class="headingAnchor" id="H1159722949"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The etiology of metabolic acidosis in children can be separated into three pathogenetic mechanisms  (<a class="graphic graphic_table graphicRef51117" href="/z/d/graphic/51117.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Increase in acid concentration either due to increased acid generation (endogenous production or exogenous ingestion/infusions) or decreased kidney acid excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of bicarbonate (HCO<sub>3</sub>) via the intestine or kidneys.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilution of serum HCO<sub>3</sub> concentrations by nonbicarbonate/acetate/lactate-containing solutions with a resultant rise in blood hydrogen ions (H<sup>+</sup>) concentrations.</p><p></p><p class="headingAnchor" id="H2039077661"><span class="h2">Increased acid concentration: High anion gap metabolic acidosis</span><span class="headingEndMark"> — </span>A high anion gap (AG) metabolic acidosis is due to the overproduction of endogenous acids, excessive intake of exogenous acids (eg, salicylates), or accumulation of acids due to the kidney's inability to excrete acid in sufficient quantities to maintain normal serum HCO<sub>3</sub> concentrations.</p><p>A frequently used mnemonic to identify the more common causes of AG metabolic acidosis in children is MUDPILES (where M = methanol; U = uremia; D = diabetic ketoacidosis; P = <a class="drug drug_general" data-topicid="83875" href="/z/d/drug information/83875.html" rel="external">paraldehyde</a>; I = iron, <a class="drug drug_pediatric" data-topicid="13393" href="/z/d/drug information/13393.html" rel="external">isoniazid</a>, and inborn metabolic errors; L = lactic acid; E= ethylene glycol; and S = salicylates).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>M</strong>ethanol, or wood alcohol, when ingested in excessive quantities, causes an increase in serum formaldehyde, which is converted to formate and formic acid. These metabolites inhibit cytochrome oxidation, leading to progressive acidosis due to the rise of blood lactic acid and ketoacid concentrations [<a href="#rid1">1</a>]. The osmolal gap can be useful in detecting the ingestion of methanol. (See  <a class="medical medical_review" href="/z/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2334.html" rel="external">"Serum osmolal gap"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>U</strong>remia in patients with acute or chronic kidney failure is associated with reduced acid excretion by the kidneys resulting in an accumulation of lactic acid, hippuric acid, amino acids [<a href="#rid2">2</a>], pyroglutamic acid [<a href="#rid2">2</a>], guanidinosuccinic acid [<a href="#rid3">3</a>], short-chain fatty acids [<a href="#rid3">3</a>], and sulfuric acid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>D</strong>iabetic ketoacidosis (hyperglycemia due to insulin deficiency) results in excess serum levels of acetoacetate (acetoacetic acid), L-lactate/D-lactate, and beta-hydroxybutyrate [<a href="#rid4">4</a>]. Ketosis due to either starvation or ketogenic diet can also cause AG metabolic acidosis. Ketosis results in increased serum levels of acetoacetate (acetoacetic acid) and beta-hydroxybutyrate and ketones in the urine [<a href="#rid5">5-7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P</strong>araldehyde administration is reported to increase serum concentrations of lactic acid [<a href="#rid8">8</a>]. The inclusion of <a class="drug drug_general" data-topicid="83875" href="/z/d/drug information/83875.html" rel="external">paraldehyde</a> is more historical as it is no longer available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>I</strong>nborn errors of metabolism can present with metabolic acidosis due to accumulation of lactic acid, ketoacids, and methylmalonic acid depending on the underlying etiology  (<a class="graphic graphic_table graphicRef76373" href="/z/d/graphic/76373.html" rel="external">table 2</a>). In particular, metabolic acidosis is a predominant finding of organic acidemias (methylmalonic, propionic, and isovaleric acidemia, glutaric acidemia type 1, 3-methylglutaconic aciduria  (<a class="graphic graphic_table graphicRef50227" href="/z/d/graphic/50227.html" rel="external">table 3</a>)) and also observed in children with maple syrup urine disease and disorders of carbohydrate production (eg, pyruvate carboxylase, pyruvate dehydrogenase, and phosphoenolpyruvate carboxykinase deficiency)  (<a class="graphic graphic_table graphicRef56040" href="/z/d/graphic/56040.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Metabolic acidosis'</a> and  <a class="medical medical_review" href="/z/d/html/2930.html" rel="external">"Inborn errors of metabolism: Classification"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>I</strong>ron overdose can cause a high AG metabolic acidosis from accumulation of lactic acid due to the complications of dissociated ferrous or ferric molecules, including intestinal ulceration, fulminant liver failure, and decreased cardiac output [<a href="#rid9">9</a>]. "I" also may refer to other possible ingestions that are associated with metabolic acidosis  (<a class="graphic graphic_table graphicRef58822" href="/z/d/graphic/58822.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>I</strong>soniazid overdose is characterized by seizures, coma, and metabolic acidosis due to elevated levels of ketoacids [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L</strong>actic acidosis occurs when lactate is overproduced or underutilized. In children, causes of lactic acidosis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conditions associated with shock result in increased lactate acid due to impaired tissue oxygenation, such as sepsis, cardiac failure, and severe hypoxia. Elevated lactate levels &gt;36 mg/dL measured in children with sepsis have been correlated with a high mortality [<a href="#rid13">13</a>] (See  <a class="medical medical_review" href="/z/d/html/2370.html" rel="external">"Causes of lactic acidosis", section on 'Type A lactic acidosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Underlying mitochondrial dysfunction, either congenital  (<a class="graphic graphic_table graphicRef69937" href="/z/d/graphic/69937.html" rel="external">table 6</a>) or acquired due to fasting [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/2930.html" rel="external">"Inborn errors of metabolism: Classification", section on 'Mitochondrial disorders'</a> and  <a class="medical medical_review" href="/z/d/html/2370.html" rel="external">"Causes of lactic acidosis", section on 'Mitochondrial dysfunction'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe crush injury resulting in rhabdomyolysis resulting in lactic acidosis due to muscle ischemia. (See  <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis", section on 'Fluid and electrolyte abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>E</strong>thylene glycol poisoning causes increased levels of lactic acid and ketoacids [<a href="#rid15">15</a>]. The osmolal gap is useful in detecting ingestion of ethylene glycol as well as methanol and ethanol. (See  <a class="medical medical_review" href="/z/d/html/2334.html" rel="external">"Serum osmolal gap"</a> and  <a class="medical medical_review" href="/z/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>S</strong>alicylate toxicity in children produce elevated levels of salicylic acid, ketoacids, and lactic acid [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H1549959089"><span class="h2">Loss of bicarbonate: Normal anion gap metabolic acidosis</span><span class="headingEndMark"> — </span>Normal AG (also referred to as non-AG) metabolic acidosis occurs with a loss of serum HCO<sub>3</sub>, which is matched with a concomitant rise in serum chloride (hyperchloremic metabolic acidosis).</p><p>The following causes should be considered in a child who presents with normal AG metabolic acidosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal losses of HCO</strong><strong><sub>3</sub></strong> due to diarrhea, small bowel, or pancreatic drainage cause a significant reduction in serum HCO<sub>3</sub> concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney losses of HCO</strong><strong><sub>3</sub></strong> or the inability to acidify the urine, as is seen with renal tubular acidosis (RTA), leads to a hyperchloremic metabolic acidosis. (See  <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">"Etiology and clinical manifestations of renal tubular acidosis in infants and children"</a>.)</p><p></p><p class="bulletIndent1">Carbonic anhydrase inhibitors, like <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a>, decrease conversion of carbonic acid to water and carbon dioxide (CO<sub>2</sub>) at the renal tubule brush border resulting in HCO<sub>3</sub> loss and, subsequently, metabolic acidosis. (See  <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">"Mechanism of action of diuretics", section on 'Carbonic anhydrase inhibitors (acetazolamide)'</a>.)</p><p></p><p class="headingAnchor" id="H2650547166"><span class="h2">Mixed high anion and normal gap acidosis</span><span class="headingEndMark"> — </span>Occasionally, there are pediatric patients who have mixed causes of metabolic acidosis, where both high and normal AG causes coexist. (See <a class="local">'Mixed anion gap'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>In certain situations, children with chronic kidney disease (CKD) can have both accumulated acids (high AG acidosis due to uremia) and RTA (normal gap acidosis with the inability to excrete adequate H<sup>+</sup> and/or the loss of HCO<sub>3</sub>) occur at the same time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children recovering from ketoacidosis may still have elevated serum ketoacids that are converted back to HCO<sub>3</sub>. However, if ketoacid anions are lost in urine before they can be metabolized (as sodium or potassium salts), they represent lost potential HCO<sub>3</sub>. The effect of these urinary losses is that most patients with diabetic ketoacidosis with initial high AG acidosis develop a normal AG metabolic acidosis during their recovery phase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with severe diarrhea have a normal AG due to loss of HCO<sub>3</sub>, but, if severe hypovolemia develops, high AG metabolic acidosis may develop due to increased lactic acid production (poor tissue perfusion) and impaired acid excretion by the kidney. These patients with hypovolemic shock require fluid resuscitation to restore tissue perfusion. (See  <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Volume and rate'</a>.)</p><p></p><p class="headingAnchor" id="H2519036036"><span class="h2">Dilutional metabolic acidosis</span><span class="headingEndMark"> — </span>Dilutional acidosis refers to a fall in serum HCO<sub>3</sub> concentration that is due to expansion of the intravascular fluid volume with large volumes of intravenous (IV) fluids containing neither HCO<sub>3</sub> nor the sodium salts of organic anions that can be metabolized to HCO<sub>3</sub> (such as lactate or acetate). Dilutional metabolic acidosis has been reported in children who receive parenteral fluids following trauma or those undergoing surgery [<a href="#rid17">17-20</a>]. Dilution-induced metabolic acidosis is usually mild and often associated with clinical signs of fluid overload (periorbital or pretibial edema, pleural effusions, ascites), fluid intake greatly in excess of urine output, and increases in patient weight. Laboratory studies that support a diagnosis of dilutional-induced acidosis include a low serum chloride, low serum uric acid, low blood urea nitrogen, low serum osmolality, and high beta-type natriuretic peptide.</p><p>The underlying mechanism of dilutional acidosis remains unknown as the dilution of both serum HCO<sub>3</sub> and H<sup>+</sup> with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> is proportional. Proposed mechanisms include [<a href="#rid21">21,22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CO<sub>2</sub> from the lungs equilibrates with lower CO<sub>2</sub> in the diluted blood and becomes hydrated to carbonic acid</p><p class="bulletIndent1"><span class="glyph">●</span>Normal cellular metabolism contributes to the H<sup>+</sup></p><p></p><p class="headingAnchor" id="H4227473628"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>There are no distinguishing clinical features of pediatric metabolic acidosis. Findings are nonspecific and vary between the acute and chronic disorders.</p><p class="headingAnchor" id="H3366770793"><span class="h2">Acute metabolic acidosis</span><span class="headingEndMark"> — </span>Children with acute metabolic acidosis typically present with symptoms related to the underlying condition and may also have signs/symptoms of compensatory respiratory alkalosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachypnea and hypernea</strong> – The most common manifestations of acute metabolic acidosis in children are tachypnea and/or hyperpnea due to compensatory respiratory compensation. Older children can exhibit an increase in respiratory rate (tachypnea) and depth of respiration (eg, Kussmaul respirations). In young children and infants, the increase in depth of respiration, as observed in classic Kussmaul breathing, may not be as apparent and tachypnea may be the only response to metabolic acidosis. An inability to generate an appropriate hyperventilatory response may be indicative of significant underlying neurologic and/or respiratory disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic findings</strong> – Mental confusion and lethargy have been observed in patients with severe acute metabolic acidosis, despite minor changes in cerebrospinal and brain pH [<a href="#rid23">23</a>]. As an example, children with severe metabolic acidosis due to diabetic ketoacidosis generally present with lethargy, altered mental status, seizures, ataxia, hypotonia, muscle weakness, and developmental delay, as well as vision and hearing impairments [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Partial pressure of carbon dioxide (PCO<sub>2</sub>) – The respiratory alkalotic compensation results in a decrease in the PCO<sub>2</sub> concentrations, which raise the blood pH toward normal, although usually never complete and never overcompensated. The respiratory compensation for metabolic acidosis generates a relatively linear relationship between the arterial PCO<sub>2</sub> and bicarbonate (HCO<sub>3</sub>) concentration, with a decreased of PCO<sub>2</sub> of 1.2 mmHg for every 1 mmol/L decrease in serum HCO<sub>3</sub>. This respiratory response to metabolic acidosis begins within 30 minutes and is complete by 12 to 24 hours. (See  <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis", section on 'Determination of whether respiratory compensation is appropriate'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperkalemia – Acute metabolic acidosis can precipitate hyperkalemia, which, if severe, is associated with life-threatening cardiac conduction abnormalities. (See <a class="local">'Effect of acidemia on potassium and ionized calcium and magnesium levels'</a> below and  <a class="medical medical_review" href="/z/d/html/14274.html" rel="external">"Causes, clinical manifestations, diagnosis, and evaluation of hyperkalemia in children", section on 'Cardiac conduction abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac effects</strong> – Data from animal and tissue studies showed myocardial depression and arrhythmias when the pH falls below 7.1 [<a href="#rid25">25,26</a>]. A study of critically ill adults demonstrated diminished cardiac function when blood pH was less than 7.28 [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H1104085528"><span class="h2">Chronic metabolic acidosis</span><span class="headingEndMark"> — </span>Children with chronic metabolic acidosis can be asymptomatic or present with multiple-system manifestations depending on the duration and severity of the underlying disorder. For children with long-standing uncorrected metabolic acidosis (eg, renal tubular acidosis [RTA]), findings include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor growth and skeletal muscle wasting</strong> ‒ Poor growth and skeletal muscle wasting are attributed to aberrant growth hormone secretion and resistance to insulin-like growth factors as well as rickets due to bone abnormalities [<a href="#rid28">28</a>]. Growth impairment is commonly seen in children with uncorrected acidosis due to RTA; however, adequate treatment can prevent poor growth and, in some young children, can result in catchup growth [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">"Etiology and clinical manifestations of renal tubular acidosis in infants and children"</a> and  <a class="medical medical_review" href="/z/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased bone mineral content</strong> ‒ Rickets is observed in children with chronic acidosis due to bone biochemistry abnormalities. Bone buffering of some of the excess hydrogen ions (H<sup>+</sup>) is associated with the release of calcium and phosphate from bone, resulting in a decrease in bone mineral content. Chronic acidosis decreases osteoblast activity and increases osteoclastic activity [<a href="#rid30">30</a>]. Treatment of chronic metabolic acidosis improves bone mineral density and rickets, as well as linear growth in these children [<a href="#rid29">29,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease", section on 'Prevention of bone buffering'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrolithiasis and nephrocalcinosis</strong> ‒ Hypercalciuria in children with chronic metabolic acidosis increases the risk of nephrolithiasis and nephrocalcinosis. For example, children with distal (type 1) RTA have an increased risk of nephrolithiasis and nephrocalcinosis. Calcium is mobilized from the bone, resulting in increased calcium excretion by the kidney [<a href="#rid32">32</a>]. In addition, the hypocitraturia that occurs in response to metabolic acidosis enhances proximal tubular citrate reabsorption, which limits tubular calcium reabsorption, leading to kidney calculi (stone) formation [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/6112.html" rel="external">"Kidney stones in children: Epidemiology and risk factors", section on 'Hypocitraturia'</a> and  <a class="medical medical_review" href="/z/d/html/6125.html" rel="external">"Nephrocalcinosis in neonates", section on 'Hypocitraturia'</a> and  <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">"Etiology and clinical manifestations of renal tubular acidosis in infants and children", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H3532586535"><span class="h2">Neonates</span><span class="headingEndMark"> — </span>Newborns and infants are more vulnerable to developing metabolic acidosis than are older children and adults as they have a lower kidney capacity for net acid excretion [<a href="#rid34">34</a>].</p><p>Infants with perinatal asphyxia are at risk for metabolic acidosis due to increased blood lactic acid concentrations, which can be detected in umbilical cord samples [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/4975.html" rel="external">"Perinatal asphyxia in term and late preterm infants", section on 'Basic laboratory tests'</a>.)</p><p>The clinical determination of a (serum) chloride:sodium ratio (&lt;0.75) has been reported to be useful in identifying these infants as they have a normal chloride or hypochloremic metabolic acidosis due to an anion gap (AG) metabolic acidosis [<a href="#rid37">37</a>]. (See <a class="local">'Dilutional metabolic acidosis'</a> above.)</p><p class="headingAnchor" id="H571931039"><span class="h1">LABORATORY TESTS</span></p><p class="headingAnchor" id="H2312665285"><span class="h2">Detection: Electrolyte panel and blood gas measurements</span><span class="headingEndMark"> — </span>Metabolic acidosis is typically detected by a low serum total carbon dioxide (CO<sub>2</sub>) in an electrolyte panel and, less commonly, by a low bicarbonate (HCO<sub>3</sub>) concentration in a blood gas sample. The total serum CO<sub>2</sub>, which is routinely reported in serum electrolyte panels, includes measurements of serum HCO<sub>3</sub> (95 percent of total CO<sub>2</sub>), dissolved CO<sub>2</sub>, and carbonic acid. In contrast, arterial and venous blood gas measurements separately report total HCO<sub>3</sub> values and the partial pressure of CO<sub>2</sub> (PCO<sub>2</sub>). In some clinical settings, the diagnosis may be apparent without a blood gas measurement of pH (eg, diabetic ketoacidosis). As a rule of thumb, serum total CO<sub>2</sub> concentrations lower than 14 mmol/L are due to metabolic acidosis, not as compensation for a respiratory alkalosis. (See <a class="local">'Confirmation of primary metabolic acidosis'</a> below.)</p><p class="headingAnchor" id="H2241988017"><span class="h2">Normative total carbon dioxide and bicarbonate levels by age</span><span class="headingEndMark"> — </span>Serum total CO<sub>2</sub> and HCO<sub>3</sub> concentrations vary with age [<a href="#rid38">38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>18 to 40 years of age – 23 to 30 mmol/L [<a href="#rid39">39</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;2 to 18 years – 22 to 26 mmol/L [<a href="#rid40">40,41</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Infants to 2 years – 16 to 24 mmol/L</p><p></p><p>Newborn infants normally have lower serum HCO<sub>3</sub> concentrations compared with older infants and children. The lower normal values are due to their lower renal plasma HCO<sub>3</sub> threshold with increased urinary losses and their lower capacity to excrete an acid load, resulting in a greater risk to develop metabolic acidosis and a reduced regeneration and reabsorption of HCO<sub>3</sub> in the proximal renal tubule. Both HCO<sub>3</sub> reabsorption and kidney acid excretion improve rapidly during the first few days to weeks of life, resulting in higher levels of HCO<sub>3</sub> [<a href="#rid34">34,42</a>]. (See  <a class="medical medical_review" href="/z/d/html/111976.html" rel="external">"Neonatal acute kidney injury: Evaluation, management, and prognosis", section on 'Metabolic acidosis'</a>.)</p><p class="headingAnchor" id="H3188088464"><span class="h2">Effect of acidemia on potassium and ionized calcium and magnesium levels</span><span class="headingEndMark"> — </span>Metabolic acidosis can affect the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum/plasma potassium (K</strong><strong><sup>+</sup></strong><strong>)</strong> – Serum/plasma K<sup>+</sup> increases with increasing acidemia (decreasing pH). For every decrease in the blood pH by 0.1, the serum potassium increases by 0.6 mEq/L.</p><p></p><p class="bulletIndent1">There is a diffusion-based equilibration of hydrogen ions (H<sup>+</sup>) between extracellular and intracellular spaces so that when serum H<sup>+</sup> concentrations are high, there is a net influx of H<sup>+</sup> into the cells. Serum/plasma K<sup>+</sup> concentrations rise due to the exchange of intracellular K<sup>+</sup> for extracellular H<sup>+</sup>. Sodium is incapable of moving intracellularly in response to the H<sup>+</sup> diffusion due to the presence of the sodium-potassium ATPase (Na<sup>+</sup>/K<sup>+</sup>-ATPase) [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/14274.html" rel="external">"Causes, clinical manifestations, diagnosis, and evaluation of hyperkalemia in children", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ionized calcium and magnesium</strong> – Ionized calcium and magnesium increase with increasing acidemia [<a href="#rid44">44</a>]. When H<sup>+</sup> competes with calcium and magnesium for binding sites on albumin and other serum proteins, calcium and magnesium are displaced from their protein binding sites, resulting in an increase in ionized (free) calcium and magnesium ions in the serum/plasma. Ionized magnesium changes 0.12 mmol/L per pH unit, and ionized calcium changes 0.36 mmol/L per pH unit [<a href="#rid44">44</a>]. Conversely, correction of the acidosis (eg, HCO<sub>3</sub> therapy) may lead to clinically significant decreases in ionized calcium and magnesium levels. (See  <a class="medical medical_review" href="/z/d/html/845.html" rel="external">"Relation between total and ionized serum calcium concentrations", section on 'Acid-base disorders'</a>.)</p><p></p><p class="headingAnchor" id="H1154256859"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>A diagnostic evaluation that includes serum or plasma electrolytes, calculation of the anion gap (AG), and elements from the history and physical examination are usually sufficient to determine the cause of the metabolic acidosis and guide therapy  (<a class="graphic graphic_algorithm graphicRef129065" href="/z/d/graphic/129065.html" rel="external">algorithm 1</a>). In some cases, a blood gas measurement is needed to confirm primary metabolic acidosis from compensated respiratory alkalosis.</p><p class="headingAnchor" id="H2918279260"><span class="h2">Confirmation of primary metabolic acidosis</span><span class="headingEndMark"> — </span>If metabolic acidosis is tentatively identified by a low total carbon dioxide (CO<sub>2</sub>) on an electrolyte panel measurement, an arterial or venous blood gas sample may be needed to differentiate metabolic acidosis from compensated respiratory alkalosis as a low bicarbonate (HCO<sub>3</sub>) level may be observed in both conditions. If the patient has a simple metabolic acidosis, then the patient will be acidemic with a pH &lt;7.35. If the patient has a primary respiratory alkalosis with compensated metabolic acidosis, the patient is alkalemic with a pH &gt;7.42. (See <a class="local">'Detection: Electrolyte panel and blood gas measurements'</a> above and  <a class="medical medical_review" href="/z/d/html/2352.html" rel="external">"Simple and mixed acid-base disorders"</a>.)</p><p>In the following two examples, the HCO<sub>3</sub> level is 18 mmol/L and the pH from a blood gas example differentiates between the two processes.</p><p class="bulletIndent1"><span class="glyph">●</span>Primary metabolic acidosis with an incomplete compensatory respiratory alkalosis – pH 7.34, partial pressure of CO<sub>2</sub> (PCO<sub>2</sub>) 35 mmHg, HCO<sub>3</sub> 18 mmol/L</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary acute respiratory alkalosis with an incomplete compensatory metabolic acidosis – pH 7.46, PCO<sub>2</sub> 29 mmHg, HCO<sub>3</sub> 18 mmol/L</p><p></p><p>Blood gas PCO<sub>2</sub> values can assist in determining the primary acid-base derangement:</p><p class="bulletIndent1"><span class="glyph">●</span>If the primary acid-base perturbation is metabolic acidosis, then the PCO<sub>2</sub> should drop by 1.2 mmHg for every 1 mmol/L drop in serum total CO<sub>2</sub> concentration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the primary acid-base perturbation is respiratory alkalosis, then the serum total CO<sub>2</sub> concentration should decrease by 5 mmol/L for every 10 mmHg decrease in PCO<sub>2</sub>.</p><p></p><p class="headingAnchor" id="H2091884883"><span class="h2">Anion gap</span><span class="headingEndMark"> — </span>Once a metabolic acidosis diagnosis has been confirmed, serum electrolyte values are used to determine the serum AG  (<a class="graphic graphic_algorithm graphicRef129065" href="/z/d/graphic/129065.html" rel="external">algorithm 1</a>). The serum AG is defined as the difference between measured cations and measured anions. (See  <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis", section on 'Assessment of the serum anion gap'</a>.)</p><p>Several equations may be used:</p><p class="bulletIndent1"><span class="glyph">●</span>Because sodium (Na) is the primary measured cation and chloride (Cl) and HCO<sub>3</sub> are the primary measured anions, most institutions, including our center, use the following formula to determine the AG (<a class="calc calc_professional" href="/z/d/html/15607.html" rel="external">calculator 1</a>):</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Serum AG = Na – (Cl + HCO<sub>3</sub>)</p></div></div><p></p><p class="bulletIndent1">The normal value of the serum AG depends on the specific chemical analyzers used to measure each analyte and, therefore, will vary from laboratory to laboratory and over time. In general, the normal AG range using this formula is approximately 4 to 12 mEq/L. However, it is best for each laboratory to determine its own local normative range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other centers, particularly outside of the United States, include the potassium (K) as a measured cation and use the following formula:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Serum AG = (Na + K) – (Cl + HCO<sub>3</sub>)</p></div></div><p></p><p class="bulletIndent1">The normal range for this formula is 4 mEq/L higher than in the preceding formula because the normal value of K used in this formula is 4 mEq/L.</p><p></p><p>Interpretation of the serum AG is most helpful when an individual's usual, or baseline, AG is known and serial measurements are available from the same laboratory. As an example, if a patient's baseline AG is 4 mEq/L and a subsequent measurement is 12 mEq/L, then the 8 mEq/L increase in AG is probably clinically significant despite the fact that the AG is still within the "normal" range.</p><p>For children with hypoalbuminemia, use of the above equations can underestimate the AG. To adjust for hypoalbuminemia, the following equation is used:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Corrected AG = AG + (0.25 × (4 – Albumin [in g/dL]))</p></div></div><p></p><p class="headingAnchor" id="H3147611863"><span class="h3">High anion gap</span><span class="headingEndMark"> — </span>For patients with a high AG, the etiology of their metabolic acidosis is caused by an increased acid concentration due to the presence of unmeasured anions. (See <a class="local">'Increased acid concentration: High anion gap metabolic acidosis'</a> above.)</p><p>Results from the initial basic metabolic tests, history, and physical examination are typically helpful in determining the underlying cause and, in some circumstances, guide further diagnostic evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes</strong> – Elevated blood glucose and a history of polyuria with or without weight loss, abdominal pain, and vomiting suggests diabetic ketoacidosis. Patients with diabetic ketoacidosis will also have elevated urine ketones. (See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney disease</strong> – Elevated blood urea nitrogen and serum creatinine are observed in children with uremia and impaired kidney acid excretion. (See  <a class="medical medical_review" href="/z/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis", section on 'Other laboratory findings'</a> and  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ingestion</strong> – History of accidental or intentional ingestion  (<a class="graphic graphic_table graphicRef58822" href="/z/d/graphic/58822.html" rel="external">table 5</a>). If the type of ingestion is unknown, determination of the serum osmolal gap might help distinguish between different types of ingestions. First, measure the serum osmolality and electrolytes. Next, determine the calculated serum osmolality, using a calculator (<a class="calc calc_professional" href="/z/d/html/13498.html" rel="external">calculator 2</a> and <a class="calc calc_professional" href="/z/d/html/13495.html" rel="external">calculator 3</a>) or the following formula (using conventional units):</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Calculated serum osmolality = (2 × Na) + (Blood urea nitrogen/2.8) + Serum glucose/18</p></div></div><p></p><p class="bulletIndent1">Then, calculate the osmolal gap, which is the difference between measured and calculated serum osmolalities.</p><p></p><p class="bulletIndent1">In the presence of a high AG metabolic acidosis, a high osmolal gap (eg, &gt;10 to 15 mOsm/L) suggests ethylene glycol, ethanol, or methanol ingestion  (<a class="graphic graphic_table graphicRef62390" href="/z/d/graphic/62390.html" rel="external">table 7</a>) (see  <a class="medical medical_review" href="/z/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a>). By contrast, a normal osmolal gap (&lt;10 mOsm/L) suggests elevated levels of iron, cyanide, carboxyhemoglobin, salicylates, cocaine, or amphetamine. These toxicities can be confirmed by laboratory testing and, in some cases, rapid drug screening. (See  <a class="medical medical_review" href="/z/d/html/6498.html" rel="external">"Acute iron poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure", section on 'Diagnosis of poisoning'</a> and  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation", section on 'Serum salicylate concentration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence of poor tissue perfusion (shock)</strong> ‒ Blood lactic acid is elevated in patients with poor tissue perfusion (eg, sepsis, cardiac failure, severe hypoxia) and severe crush injuries. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a> and  <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inborn error of metabolism</strong> – Neurologic signs and symptoms including a history of severe hypotonia, seizures, developmental delay, or apnea in a newborn infant suggests the possibility of an inborn error of metabolism. Elevated lactic acid is observed in patients with mitochondrial disorders and organic acidurias. A serum ammonia level and a lactic acid:pyruvic acid ratio may be helpful in the determining the specific metabolic disorder. (See  <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder"</a>.)</p><p></p><p class="headingAnchor" id="H1710068127"><span class="h3">Normal anion gap</span><span class="headingEndMark"> — </span>Patients with metabolic acidosis and normal AG generally have an underlying disorder that results from a loss of HCO<sub>3</sub>. Most pediatric cases of metabolic acidosis with a normal AG are due to losses of HCO<sub>3</sub> from the gastrointestinal tract and are typically diagnosed based on a history of diarrhea or abnormal drainage from the small bowel or pancreas.</p><p>Determination of the urine AG may be useful if the etiology of the normal AG remains unclear. The urine AG is calculated from the following formula:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Urine AG = (Urine Na + Urine K) – Urine Cl</p></div></div><p></p><p>In the presence of metabolic acidosis, a positive urine AG value indicates impaired ammonium excretion, such as is seen in distal (type 1) and hypoaldosteronism (type 4) renal tubular acidosis (RTA). Conversely, a negative urine AG is consistent with intact urinary ammonium excretion as seen in children with metabolic acidosis due to proximal (type 2) RTA (with a very low serum total CO<sub>2</sub> concentration) and gastrointestinal losses [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/2348.html" rel="external">"Urine anion and osmolal gaps in metabolic acidosis"</a>.)</p><p class="headingAnchor" id="H3311498848"><span class="h3">Mixed anion gap</span><span class="headingEndMark"> — </span>The delta gap ratio may be helpful to confirm mixed metabolic acidosis when both high and normal AG causes coexist. However, the use of this tool assumes that the baseline serum AG and HCO<sub>3</sub> concentration are known or can be accurately estimated and that all buffering is provided by HCO<sub>3</sub> and is extracellular. (See  <a class="medical medical_review" href="/z/d/html/2292.html" rel="external">"The delta anion gap/delta HCO3 ratio in patients with a high anion gap metabolic acidosis"</a>.)</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">Delta gap ratio = Change in AG (from a normal of 12 mmol/L)/change in HCO<sub>3</sub> (from normal of 24 mmol/L)</p></div></div><p></p><p>The calculated delta gap ratio may be used to distinguish the various forms of metabolic acidosis:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;0.4 – Normal AG metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>0.4 to 0.99 – Mixed high AG and normal AG metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>1.0 to 1.6 – High AG metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;1.6 – Mixed high AG metabolic acidosis with metabolic alkalosis</p><p></p><p>In a study of adult trauma patients with measured lactic acid and HCO<sub>3</sub> values prior to intravenous (IV) hydration, the delta gap ratio was 1.86 [<a href="#rid46">46</a>]. The higher-than-expected delta gap of 1.0 was attributed to unmeasured anions.</p><p class="headingAnchor" id="H3175362681"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Whenever possible, the primary focus of therapy for metabolic acidosis should be directed at reversing the underlying pathophysiologic process. Directed treatment of the acidosis is based on whether the metabolic acidosis is acute or chronic and the severity of acidosis.</p><p class="headingAnchor" id="H662041275"><span class="h2">Acute metabolic acidosis</span><span class="headingEndMark"> — </span>Acute metabolic acidosis is generally well tolerated, but extreme acidemia can be life-threatening. The best management strategy is to treat the underlying disorder, such as septic shock or diabetic ketoacidosis.</p><p class="headingAnchor" id="H4004989206"><span class="h3">Intravenous bicarbonate therapy</span></p><p class="headingAnchor" id="H1786847282"><span class="h4">Patient selection</span><span class="headingEndMark"> — </span>The use of intravenous (IV) <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> (HCO<sub>3</sub>) therapy or other buffering agents in critically ill patients with severe acidemia remains controversial. In most cases, sodium HCO<sub>3</sub> therapy may temporarily improve or may even correct the acidemia but does not alter the underlying metabolic acidosis cause. If the underlying cause is not treated, the metabolic acidosis persists and results in subsequent reaccumulation of hydrogen ions (H<sup>+</sup>).</p><p>Our approach depends on the cause of the acidosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute kidney injury or chronic kidney failure – There may be a role for IV sodium HCO<sub>3</sub> therapy in selected patients with acute kidney injury and chronic kidney failure. In our practice, we reserve the use of IV sodium HCO<sub>3</sub> for patients with impaired kidney acid excretion (with renal tubular acidosis [RTA; if oral administration of HCO<sub>3</sub> is not possible], acute kidney injury, or chronic kidney disease [CKD]) when their blood pH &lt;7.2 or when urine alkalization is needed. This is based on indirect evidence from a randomized trial of critically ill adults who had a pH of 7.2 or less, in which sodium HCO<sub>3</sub> decreased the risk of death for patients with kidney injury but not for the entire cohort [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Bicarbonate in selected patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resuscitation – By contrast, IV sodium HCO<sub>3</sub> is generally not recommended for pediatric resuscitation, except for a few specific conditions, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6386.html" rel="external">"Primary drugs in pediatric resuscitation", section on 'Sodium bicarbonate'</a>.)</p><p></p><p>Adverse effects of IV HCO<sub>3</sub> therapy can include (see  <a class="medical medical_review" href="/z/d/html/6386.html" rel="external">"Primary drugs in pediatric resuscitation", section on 'Sodium bicarbonate'</a> and  <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis", section on 'Acute metabolic acidosis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertonicity and hypernatremia – This is caused by the high sodium load in the sodium HCO<sub>3</sub>. The 8.4 percent sodium HCO<sub>3</sub> solution has sodium concentration of 1 mEq/mL (or 1000 mEq/L). In the rare cases where large quantities of IV sodium HCO<sub>3</sub> are used, sodium HCO<sub>3</sub> should be mixed in D5 IV fluid to a concentration of 150 mEq/L to avoid hypernatremia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia – This is caused by rapid correction of a metabolic acidosis. An increase of 0.1 unit rise in pH can cause a decrease of serum/plasma potassium of 0.4 mEq/L as potassium moves intracellularly to maintain electroneutrality. (See  <a class="medical medical_review" href="/z/d/html/97159.html" rel="external">"Hypokalemia in children", section on 'Increased intracellular uptake'</a> and  <a class="medical medical_review" href="/z/d/html/2353.html" rel="external">"Potassium balance in acid-base disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypocalcemia – Ionized calcium can decrease rapidly in response to sodium HCO<sub>3</sub> administration because the binding of calcium to albumin is pH dependent. For example, if a child's blood pH increases from 7.05 to 7.3 with HCO<sub>3</sub> administration or dialysis, the ionized calcium would be expected to fall from 1.0 mmol/L to 0.87 mmol/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with diabetic ketoacidosis, HCO<sub>3</sub> administration is not recommended, because it has been associated with cerebral injury (cerebral edema) and hypokalemia and also may delay resolution of ketosis. (See  <a class="medical medical_review" href="/z/d/html/5808.html" rel="external">"Diabetic ketoacidosis in children: Treatment and complications", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid infusion of sodium HCO<sub>3</sub> may be associated with adverse cardiovascular effects, based on studies in animal models.</p><p></p><p class="headingAnchor" id="H3055483406"><span class="h4">Preadministration considerations</span><span class="headingEndMark"> — </span>If the decision is made to administer IV sodium HCO<sub>3</sub>, the clinician needs to consider the following prior to administration:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steps to avoid hypocalcemia</strong> – Ionized calcium values decrease when sodium HCO<sub>3</sub> is infused or when a patient is receiving hemodialysis with a dialysate with a high HCO<sub>3</sub> concentration. Ionized calcium levels can be quickly obtained with a blood gas measurement. Pretreatment with IV calcium is advised if:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The corrected total calcium is &lt;8.0 mg/dL (2 mmol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>The ionized calcium is &lt;1.0 mmol/L</p><p></p><p class="bulletIndent1">The pretreatment consists of IV <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a> (preferred) 100 mg/kg or IV <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a> 10 mg/kg. This is slowly infused via a central catheter or a large vein prior to infusing sodium HCO<sub>3</sub>. Failure to correct the calcium prior to the sodium HCO<sub>3</sub> infusion can lead to acute hypocalcemia due to enhanced binding of ionized calcium to serum proteins including albumin as the blood pH increases. An acute decrease in the ionized calcium concentration below 0.75 mmol/L (3 mg/dL) or a corrected calcium &lt;7 to 7.5 mg/dL can cause cardiac dysrhythmias, seizures, and/or even tetany.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compatibility with other IV mediations</strong> – Due to its higher pH, sodium HCO<sub>3</sub> can cause compatibility problems with medications that are concurrently infused. For example, precipitation of <a class="drug drug_pediatric" data-topicid="12569" href="/z/d/drug information/12569.html" rel="external">calcium carbonate</a> can occur when IV administration of <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a>/<a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a> is mixed with sodium HCO<sub>3</sub>. If there is a medication compatibility issue due to IV fluid pH, use of <a class="drug drug_pediatric" data-topicid="12793" href="/z/d/drug information/12793.html" rel="external">sodium acetate</a> instead of sodium HCO<sub>3</sub> is a good option.</p><p></p><p class="headingAnchor" id="H97148993"><span class="h4">Administration and dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency setting</strong> – In an emergency, either 4.2 or 8.4 percent sodium HCO<sub>3</sub> solution is administered at a dose of 1 mEq/kg up to a maximum dose of 50 mEq, as an IV slow push. Five to 15 minutes after administration, blood gas, ionized calcium, and serum electrolytes are obtained to determine therapy effectiveness and/or if there has been an adverse effect of HCO<sub>3</sub> therapy (ie, low ionized calcium and hypokalemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonemergency setting repletion</strong> – In a nonemergent setting, the dosing of sodium HCO<sub>3</sub> is determined by the calculated estimated HCO<sub>3</sub> deficit using the following formula:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Estimated HCO<sub>3</sub> deficit = (Target HCO<sub>3</sub> – Current HCO<sub>3</sub>) × Weight (in kg) × 0.5</p></div></div><p></p><p class="bulletIndent1">One-half of the estimated HCO<sub>3</sub> deficit is infused IV over two to four hours. The remaining one-half of the HCO<sub>3</sub> deficit is infused over the following 6 to 24 hours. A longer course of infusion should be prescribed when the sodium HCO<sub>3</sub> deficit is large (&gt;3 mEq/kg).</p><p></p><p class="bulletIndent1">During and after repletion of the HCO<sub>3</sub> deficit, blood gas, ionized calcium, and serum electrolytes are obtained to determine whether additional HCO<sub>3</sub> therapy is required and to detect any adverse effect of HCO<sub>3</sub> therapy (low ionized calcium and hypokalemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing replacement therapy</strong> directed at HCO<sub>3</sub> loss or H<sup>+</sup> accumulation – To achieve a goal of normalizing serum HCO<sub>3</sub>, the total dose of sodium HCO<sub>3</sub> delivered over the course of a day should include not only the amount for repletion but also the maintenance dose of sodium HCO<sub>3</sub> needed to replace ongoing HCO<sub>3</sub> loss or buffer new H<sup>+</sup> accumulation. For example, patients with acute metabolic acidosis due to advanced CKD or distal RTA may require an additional 1 to 2 mEq/kg/day of sodium HCO<sub>3</sub> to maintain normal serum total carbon dioxide (CO<sub>2</sub>) concentrations.</p><p></p><p class="bulletIndent1">When the patient can tolerate oral medications, maintenance administration should be changed to an oral alkali  (<a class="graphic graphic_table graphicRef128459" href="/z/d/graphic/128459.html" rel="external">table 8</a>).</p><p></p><p class="headingAnchor" id="H1884285405"><span class="h3">Kidney replacement therapy</span><span class="headingEndMark"> — </span>Dialysis and/or continuous kidney replacement therapy may be needed for treatment of severe, life-threatening metabolic acidosis unresponsive to medical therapy, especially if it is associated with other electrolyte abnormalities including hyperkalemia. (See  <a class="medical medical_review" href="/z/d/html/15895.html" rel="external">"Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy"</a>.)</p><p class="headingAnchor" id="H1488214079"><span class="h2">Chronic metabolic acidosis</span><span class="headingEndMark"> — </span>Children with chronic acidosis typically require consistent administration of exogenous oral alkali preparations to correct the acidosis, thereby preventing the clinical manifestations of chronic acidosis. We begin alkali therapy in children with a primary renal non-anion gap (AG) metabolic acidosis (CKD and RTA) and a persistent serum total CO<sub>2</sub> &lt;21 mmol/L.</p><p>Alkali therapy includes a number of formulations of sodium HCO<sub>3</sub>, sodium citrate/citric acid, <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">potassium citrate</a>/citric acid, and combination of sodium citric acid and potassium citrate and citric acid  (<a class="graphic graphic_table graphicRef128459" href="/z/d/graphic/128459.html" rel="external">table 8</a>). The choice of therapy is dependent on the underlying cause of chronic metabolic acidosis, availability and cost of the specific medication, and experience of the prescribing clinician.</p><p>In our practice, the choice of alkali therapy and dosing are based on the underlying etiology:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distal or proximal RTA without hypokalemia</strong> – RTA can be effectively treated with <a class="drug drug_pediatric" data-topicid="16774" href="/z/d/drug information/16774.html" rel="external">sodium citrate-citric acid</a> therapy. Sodium HCO<sub>3</sub> can also be used but is less preferred because of the risk of nephrocalcinosis. The amount of HCO<sub>3</sub> equivalent needed in children with distal RTA is normally 1 to 2 mEq/kg/day. Children with proximal RTA need a much higher oral alkali dose (5 to 10 mEq/kg/day) due to the increased urinary HCO<sub>3</sub> loss, which increases with therapy. Oral alkali treatment doses are typically divided three or four times daily in infants and two to three times daily in older children. (See  <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RTA with hypokalemia</strong> – This condition requires potassium supplementation. For most children, we use an oral liquid formulation of <a class="drug drug_pediatric" data-topicid="16047" href="/z/d/drug information/16047.html" rel="external">sodium citrate-potassium citrate-citric acid</a>, which delivers 1 mEq K, 1 mEq Na, and citrate equivalent to 2 mEq HCO<sub>3</sub> per mL. The initial dose varies depending on the type of RTA: For distal RTA, we use 2 mEq/kg HCO<sub>3</sub> equivalent, and, for proximal RDA, we use 4 mEq/kg HCO<sub>3</sub> equivalent [<a href="#rid48">48</a>]. Children with more severe hypokalemia may require <a class="drug drug_pediatric" data-topicid="16457" href="/z/d/drug information/16457.html" rel="external">potassium citrate-citric acid</a> therapy, which delivers 2 mEq K and citrate equivalent to 2 mEq HCO<sub>3</sub> per mL. Some clinicians use a combination of <a class="drug drug_pediatric" data-topicid="16774" href="/z/d/drug information/16774.html" rel="external">sodium citrate-citric acid</a> and potassium citrate-citric acid therapy to allow the separate adjustment of alkali and potassium dosing in children who cannot be successfully treated with a single formulation of oral alkali. (See  <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrolithiasis</strong> – Children who have nephrolithiasis due to hypocitraturia are best treated with either oral liquid citric acid <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">potassium citrate</a> or potassium citrate tablet therapy, with an initial starting dose of approximately 1 mEq/kg/day. Urine pH and serum potassium and total CO<sub>2</sub> concentrations should be monitored to ensure that urine pH does not rise to the point where calcium- and phosphate-based calculi formation increases and the patient develops a metabolic alkalosis or hyperkalemia.</p><p></p><p class="bulletIndent1">To maintain relatively stable acid-base control, oral potassium-based alkali treatment doses are typically divided three or four times daily in infants and two to three times daily in older children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney failure</strong> – For children with metabolic acidosis in association with chronic kidney failure, the goal of therapy is to maintain a total CO<sub>2</sub> at or above 22 mEq/L. We initially begin sodium HCO<sub>3</sub> therapy at 1 mEq/kg per day divided into two to three doses, and the dose is increased until the clinical target is reached. Citrate preparations should be used with caution in children with CKD because they may promote aluminum absorption. Potassium-based alkali therapy should be generally avoided due to the risk of developing hyperkalemia. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Metabolic acidosis'</a>.)</p><p></p><p class="bulletIndent1">When alkali therapy is initiated, the smallest dose should be used and increased in a stepwise fashion until the targeted total CO<sub>2</sub> level is reached. Ongoing testing includes monitoring acid-base status (blood gas sample), serum sodium, calcium, potassium, and urine calcium/urine creatinine ratios. The additional sodium load with sodium-based oral alkali can increase urinary calcium excretion, which may worsen the nephrocalcinosis frequently seen in children with distal RTA.</p><p></p><p class="bulletIndent1">For children with chronic metabolic acidosis, consistent administration of exogenous oral alkali preparations to correct acidosis can help prevent the clinical manifestations of chronic acidosis, including poor growth, bone abnormalities, and nephrolithiasis. The effect of metabolic acidosis on height was shown in an observational study in children with CKD in which metabolic acidosis was associated with lower height Z-score and persistent alkali therapy use was associated with better height Z-scores [<a href="#rid49">49</a>]. In children with glomerular disease, low HCO<sub>3</sub> concentrations have been linked to a higher risk of CKD progression and resolution of low HCO<sub>3</sub> was associated with a lower risk of CKD progression [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">The Mediterranean diet may help to prevent and correct metabolic acidosis in the early stages of CKD, while the low-protein diet and the vegan low-protein diet are more effective in the advanced stages of CKD [<a href="#rid51">51</a>].</p><p></p><p>For infants and young children, sodium HCO<sub>3</sub> and <a class="drug drug_pediatric" data-topicid="16774" href="/z/d/drug information/16774.html" rel="external">sodium citrate-citric acid</a> are normally provided as oral liquids. However, administration can be challenging due to poor palatability and burping is a common side effect due to the rapid conversion of HCO<sub>3</sub> into water and CO<sub>2</sub> in the acidic environment of the stomach. If these problems occur, oral alkali can be mixed into formula or food to improve palatability and reduce burping. When alkali is mixed into formula, it is essential to ensure that the entire volume of formula has been consumed, otherwise the infant will not receive the full alkali dose.</p><p>Finally, it is important to recognize that administering oral alkali three or more times per day to a child can be extremely challenging. Before making an oral alkali dose adjustment based on a laboratory result, it is important to ask the family or caregivers, in a noncritical manner, whether they have been able to adhere to the prescribed dosing. If the serum total CO<sub>2</sub> is low and reported dosing by the family falls short of the prescribed amount, encourage the family to give the appropriate dose and repeat the laboratory testing rather than increase the oral alkali dose.</p><p class="headingAnchor" id="H433631656"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Metabolic acidosis is a biochemical abnormality resulting in an increase in hydrogen ions (H<sup>+</sup>) in the serum or plasma. It can be either an acute or chronic process and is secondary to a wide range of underlying disorders.</p><p></p><p class="bulletIndent1">The etiology of metabolic acidosis in children can be classified based on pathogenesis  (<a class="graphic graphic_table graphicRef51117" href="/z/d/graphic/51117.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Accumulation of H</strong><strong><sup>+</sup></strong> – Increased acid concentration (H<sup>+</sup>) can be caused by overproduction of endogenous acids, excessive intake of exogenous acids, or accumulation of acids due to the kidney's inability to excrete acid in sufficient quantities. This causes metabolic acidosis with a high anion gap (AG). (See <a class="local">'Increased acid concentration: High anion gap metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Loss of bicarbonate (HCO</strong><strong><sub>3</sub></strong><strong>)</strong> – Loss of HCO<sub>3</sub> from the gastrointestinal tract or kidneys causes metabolic acidosis with a normal AG. (See <a class="local">'Loss of bicarbonate: Normal anion gap metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mixed mechanisms</strong> – A mixed metabolic acidosis occurs when children have coexisting conditions with high and normal AG. (See <a class="local">'Mixed high anion and normal gap acidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dilutional</strong> – Dilutional metabolic acidosis is caused by a fall in serum HCO<sub>3</sub> concentration due to expansion of the intravascular fluid volume, with large volumes of intravenous (IV) fluids that do not contain HCO<sub>3</sub>. (See <a class="local">'Dilutional metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – There are no typical distinguishing clinical features of pediatric metabolic acidosis. Infants and children with acute metabolic acidosis can present with symptoms related to the underlying condition and may present with tachypnea and/or hyperpnea as signs of compensatory respiratory alkalosis. Children with chronic metabolic acidosis may have nonspecific findings including poor growth, bony abnormalities, and nephrolithiasis. Neonates are more vulnerable to developing metabolic acidosis due to their lower kidney capacity for net acid excretion. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic acidosis is typically detected by a low serum total carbon dioxide (CO<sub>2</sub>) in the electrolyte panel and, less commonly, by a low HCO<sub>3</sub> level in a blood gas sample.</p><p></p><p class="bulletIndent2">Measurement of the serum total CO<sub>2</sub> in the electrolyte panel may not be sufficient, because a low concentration can be seen in metabolic acidosis or as a compensatory response to a primary respiratory alkalosis (increased respiratory effort with lowering partial pressure of CO<sub>2</sub> [PCO<sub>2</sub>]). To distinguish between the two, a blood gas may be needed to determine the pH. If the patient has a simple metabolic acidosis, then the patient will have a low (acidic) pH and, if the patient has respiratory alkalosis with compensated metabolic acidosis, the pH should be elevated (alkalotic). (See <a class="local">'Detection: Electrolyte panel and blood gas measurements'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normative HCO<sub>3</sub> levels vary and increase from birth through late adolescence. (See <a class="local">'Normative total carbon dioxide and bicarbonate levels by age'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic acidosis increases serum/plasma potassium and ionized (free) calcium and magnesium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – After confirmation of metabolic acidosis, a diagnostic evaluation that includes serum or plasma electrolytes, calculation of the AG, and elements from the history and physical examination is usually sufficient to determine the cause of the metabolic acidosis and guide therapy  (<a class="graphic graphic_algorithm graphicRef129065" href="/z/d/graphic/129065.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Whenever possible, the primary focus of therapy for metabolic acidosis should be directed at reversing the underlying pathophysiologic process. Directed treatment of the acidosis is based on whether the metabolic acidosis is acute or chronic and the severity of acidosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IV HCO</strong><strong><sub>3</sub></strong> – We generally avoid routine administration of IV sodium HCO<sub>3</sub> to hospitalized children with metabolic acidosis and also avoid it during pediatric cardiopulmonary resuscitation. For children with acute or chronic kidney disease (CKD), IV HCO<sub>3</sub> therapy can be considered in cases of severe acidosis (pH &lt;7.2), recognizing that this is only a temporary intervention. (See <a class="local">'Intravenous bicarbonate therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney replacement therapy</strong> – Dialysis and/or continuous kidney replacement therapy may be needed for life-threatening conditions associated with metabolic acidosis, especially if it is associated with other electrolyte abnormalities such as hyperkalemia. (See <a class="local">'Kidney replacement therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/15895.html" rel="external">"Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral alkali</strong> – Children with chronic metabolic acidosis typically require consistent administration of exogenous oral alkali preparations to correct acidosis, thereby preventing the clinical manifestations of chronic acidosis (eg, poor growth, bone abnormalities, and nephrolithiasis). (See <a class="local">'Chronic metabolic acidosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2167049755"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kanwal Kher, MD, MBA, Matthew Sharron, MD, Mahesh Sharman, MD, FAAP, and Ashok Sarnaik, MD, FAAP, FCCM, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liesivuori J, Savolainen H. Methanol and formic acid toxicity: biochemical mechanisms. Pharmacol Toxicol 1991; 69:157.</a></li><li><a class="nounderline abstract_t">Sun J, Shannon M, Ando Y, et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 893-894:107.</a></li><li><a class="nounderline abstract_t">Mishima E, Fukuda S, Mukawa C, et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int 2017; 92:634.</a></li><li><a class="nounderline abstract_t">Lu J, Zello GA, Randell E, et al. Closing the anion gap: contribution of D-lactate to diabetic ketoacidosis. Clin Chim Acta 2011; 412:286.</a></li><li><a class="nounderline abstract_t">Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. J Child Neurol 2000; 15:787.</a></li><li><a class="nounderline abstract_t">Ross DL, Swaiman KF, Torres F, Hansen J. Early biochemical and EEG correlates of the ketogenic diet in children with atypical absence epilepsy. Pediatr Neurol 1985; 1:104.</a></li><li><a class="nounderline abstract_t">Huttenlocher PR. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res 1976; 10:536.</a></li><li><a class="nounderline abstract_t">Linter CM, Linter SP. Severe lactic acidosis following paraldehyde administration. Br J Psychiatry 1986; 149:650.</a></li><li class="breakAll">Hoffman RS, Nelson LS, Howland MA, et al. Goldfrank's Manual of Toxicologic Emergencies, 1st ed, McGraw Hill, 2007.</li><li><a class="nounderline abstract_t">Romero JA, Kuczler FJ Jr. Isoniazid overdose: recognition and management. Am Fam Physician 1998; 57:749.</a></li><li><a class="nounderline abstract_t">Temmerman W, Dhondt A, Vandewoude K. Acute isoniazid intoxication: seizures, acidosis and coma. Acta Clin Belg 1999; 54:211.</a></li><li><a class="nounderline abstract_t">Topcu I, Yentur EA, Kefi A, et al. Seizures, metabolic acidosis and coma resulting from acute isoniazid intoxication. Anaesth Intensive Care 2005; 33:518.</a></li><li><a class="nounderline abstract_t">Scott HF, Brou L, Deakyne SJ, et al. Association Between Early Lactate Levels and 30-Day Mortality in Clinically Suspected Sepsis in Children. JAMA Pediatr 2017; 171:249.</a></li><li><a class="nounderline abstract_t">Danhauser K, Smeitink JA, Freisinger P, et al. Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease. J Inherit Metab Dis 2015; 38:467.</a></li><li><a class="nounderline abstract_t">Saladino R, Shannon M. Accidental and intentional poisonings with ethylene glycol in infancy: diagnostic clues and management. Pediatr Emerg Care 1991; 7:93.</a></li><li><a class="nounderline abstract_t">Bartels PD, Lund-Jacobsen H. Blood lactate and ketone body concentrations in salicylate intoxication. Hum Toxicol 1986; 5:363.</a></li><li><a class="nounderline abstract_t">Sinert R, Zehtabchi S, Bloem C, Lucchesi M. Effect of normal saline infusion on the diagnostic utility of base deficit in identifying major injury in trauma patients. Acad Emerg Med 2006; 13:1269.</a></li><li><a class="nounderline abstract_t">Disma N, Mameli L, Pistorio A, et al. A novel balanced isotonic sodium solution vs normal saline during major surgery in children up to 36 months: a multicenter RCT. Paediatr Anaesth 2014; 24:980.</a></li><li><a class="nounderline abstract_t">Zunini GS, Rando KA, Cox RG. Fluid replacement in craniofacial pediatric surgery: normal saline or ringer's lactate? J Craniofac Surg 2011; 22:1370.</a></li><li><a class="nounderline abstract_t">Lima MF, Neville IS, Cavalheiro S, et al. Balanced Crystalloids Versus Saline for Perioperative Intravenous Fluid Administration in Children Undergoing Neurosurgery: A Randomized Clinical Trial. J Neurosurg Anesthesiol 2019; 31:30.</a></li><li><a class="nounderline abstract_t">Gattinoni L, Carlesso E, Maiocchi G, et al. Dilutional acidosis: where do the protons come from? Intensive Care Med 2009; 35:2033.</a></li><li><a class="nounderline abstract_t">Davenport A. Dilutional acidosis or uncovered cellular metabolism? Intensive Care Med 2009; 35:2009.</a></li><li><a class="nounderline abstract_t">Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 2010; 6:274.</a></li><li><a class="nounderline abstract_t">Roberts JS, Vavilala MS, Schenkman KA, et al. Cerebral hyperemia and impaired cerebral autoregulation associated with diabetic ketoacidosis in critically ill children. Crit Care Med 2006; 34:2217.</a></li><li><a class="nounderline abstract_t">Teplinsky K, O'Toole M, Olman M, et al. Effect of lactic acidosis on canine hemodynamics and left ventricular function. Am J Physiol 1990; 258:H1193.</a></li><li><a class="nounderline abstract_t">Orchard CH, Cingolani HE. Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994; 28:1312.</a></li><li><a class="nounderline abstract_t">Rodríguez-Villar S, Kraut JA, Arévalo-Serrano J, et al. Systemic acidemia impairs cardiac function in critically Ill patients. EClinicalMedicine 2021; 37:100956.</a></li><li><a class="nounderline abstract_t">Green J, Maor G. Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int 2000; 57:2258.</a></li><li><a class="nounderline abstract_t">Lopez-Garcia SC, Emma F, Walsh SB, et al. Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrol Dial Transplant 2019; 34:981.</a></li><li><a class="nounderline abstract_t">Bushinsky DA, Krieger NS. Effects of acid on bone. Kidney Int 2022; 101:1160.</a></li><li><a class="nounderline abstract_t">McSherry E. Acidosis and growth in nonuremic renal disease. Kidney Int 1978; 14:349.</a></li><li><a class="nounderline abstract_t">Osther PJ, Bollerslev J, Hansen AB, et al. Pathophysiology of incomplete renal tubular acidosis in recurrent renal stone formers: evidence of disturbed calcium, bone and citrate metabolism. Urol Res 1993; 21:169.</a></li><li><a class="nounderline abstract_t">Norman ME, Feldman NI, Cohn RM, et al. Urinary citrate excretion in the diagnosis of distal renal tubular acidosis. J Pediatr 1978; 92:394.</a></li><li><a class="nounderline abstract_t">Manz F, Kalhoff H, Remer T. Renal acid excretion in early infancy. Pediatr Nephrol 1997; 11:231.</a></li><li><a class="nounderline abstract_t">Allanson ER, Waqar T, White C, et al. Umbilical lactate as a measure of acidosis and predictor of neonatal risk: a systematic review. BJOG 2017; 124:584.</a></li><li><a class="nounderline abstract_t">Allanson ER, Pattinson RC, Nathan EA, Dickinson JE. The introduction of umbilical cord lactate measurement and associated neonatal outcomes in a South African tertiary hospital labor ward. J Matern Fetal Neonatal Med 2018; 31:1272.</a></li><li><a class="nounderline abstract_t">Kurt A, Ecevit A, Ozkiraz S, et al. The use of chloride-sodium ratio in the evaluation of metabolic acidosis in critically ill neonates. Eur J Pediatr 2012; 171:963.</a></li><li><a class="nounderline abstract_t">Loh TP, Metz MP. Trends and physiology of common serum biochemistries in children aged 0-18 years. Pathology 2015; 47:452.</a></li><li><a class="nounderline abstract_t">Kraut JA, Madias NE. Re-Evaluation of the Normal Range of Serum Total CO2 Concentration. Clin J Am Soc Nephrol 2018; 13:343.</a></li><li class="breakAll">Wu A. Tietz Clinical Guide to Laboratory Tests, 4th ed, Saunders, 2006.</li><li class="breakAll">Oski's Pediatrics: Principles And Practice, 4th ed, McMillan JA, Feigin RD, Deangelis MD, et al (Eds), Lippincott Williams &amp; Wilkins, 2006.</li><li><a class="nounderline abstract_t">Ramiro-Tolentino SB, Markarian K, Kleinman LI. Renal bicarbonate excretion in extremely low birth weight infants. Pediatrics 1996; 98:256.</a></li><li><a class="nounderline abstract_t">Seifter JL, Chang HY. Extracellular Acid-Base Balance and Ion Transport Between Body Fluid Compartments. Physiology (Bethesda) 2017; 32:367.</a></li><li><a class="nounderline abstract_t">Wang S, McDonnell EH, Sedor FA, Toffaletti JG. pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med 2002; 126:947.</a></li><li><a class="nounderline abstract_t">Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant 2012; 27:4273.</a></li><li><a class="nounderline abstract_t">Rudkin SE, Grogan TR, Treger RM. The Δ Anion Gap/Δ Bicarbonate Ratio in Early Lactic Acidosis: Time for Another Delta? Kidney360 2021; 2:20.</a></li><li><a class="nounderline abstract_t">Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet 2018; 392:31.</a></li><li><a class="nounderline abstract_t">Vallés PG, Batlle D. Hypokalemic Distal Renal Tubular Acidosis. Adv Chronic Kidney Dis 2018; 25:303.</a></li><li><a class="nounderline abstract_t">Brown DD, Carroll M, Ng DK, et al. Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD. Kidney360 2022; 3:666.</a></li><li><a class="nounderline abstract_t">Brown DD, Roem J, Ng DK, et al. Low Serum Bicarbonate and CKD Progression in Children. Clin J Am Soc Nephrol 2020; 15:755.</a></li><li><a class="nounderline abstract_t">Noce A, Marrone G, Wilson Jones G, et al. Nutritional Approaches for the Management of Metabolic Acidosis in Chronic Kidney Disease. Nutrients 2021; 13.</a></li></ol></div><div id="topicVersionRevision">Topic 6100 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1665561" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Methanol and formic acid toxicity: biochemical mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429878" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serum metabolomic profiles from patients with acute kidney injury: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396122" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21036159" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Closing the anion gap: contribution of D-lactate to diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11198492" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3939741" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early biochemical and EEG correlates of the ketogenic diet in children with atypical absence epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/934725" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3101931" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe lactic acidosis following paraldehyde administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3101931" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Severe lactic acidosis following paraldehyde administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490997" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Isoniazid overdose: recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10544512" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute isoniazid intoxication: seizures, acidosis and coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16119496" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Seizures, metabolic acidosis and coma resulting from acute isoniazid intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28068437" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Association Between Early Lactate Levels and 30-Day Mortality in Clinically Suspected Sepsis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25687154" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2047315" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Accidental and intentional poisonings with ethylene glycol in infancy: diagnostic clues and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3100419" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Blood lactate and ketone body concentrations in salicylate intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079786" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of normal saline infusion on the diagnostic utility of base deficit in identifying major injury in trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24824018" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A novel balanced isotonic sodium solution vs normal saline during major surgery in children up to 36 months: a multicenter RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21772178" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fluid replacement in craniofacial pediatric surgery: normal saline or ringer's lactate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912723" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Balanced Crystalloids Versus Saline for Perioperative Intravenous Fluid Administration in Children Undergoing Neurosurgery: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19763537" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dilutional acidosis: where do the protons come from?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19851752" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dilutional acidosis or uncovered cellular metabolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308999" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Metabolic acidosis: pathophysiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763506" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cerebral hyperemia and impaired cerebral autoregulation associated with diabetic ketoacidosis in critically ill children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2331007" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of lactic acidosis on canine hemodynamics and left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954638" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acidosis and arrhythmias in cardiac muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34258569" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systemic acidemia impairs cardiac function in critically Ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844596" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773598" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment and long-term outcome in primary distal renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35351460" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of acid on bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/366229" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acidosis and growth in nonuremic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8342250" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pathophysiology of incomplete renal tubular acidosis in recurrent renal stone formers: evidence of disturbed calcium, bone and citrate metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632978" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Urinary citrate excretion in the diagnosis of distal renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090674" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal acid excretion in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27704703" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Umbilical lactate as a measure of acidosis and predictor of neonatal risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28372476" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The introduction of umbilical cord lactate measurement and associated neonatal outcomes in a South African tertiary hospital labor ward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215130" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The use of chloride-sodium ratio in the evaluation of metabolic acidosis in critically ill neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26126034" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Trends and physiology of common serum biochemistries in children aged 0-18 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339355" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Re-Evaluation of the Normal Range of Serum Total CO2 Concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339355" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Re-Evaluation of the Normal Range of Serum Total CO2 Concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339355" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Re-Evaluation of the Normal Range of Serum Total CO2 Concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8692627" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Renal bicarbonate excretion in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814497" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Extracellular Acid-Base Balance and Ion Transport Between Body Fluid Compartments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12171493" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : pH effects on measurements of ionized calcium and ionized magnesium in blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235953" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35368826" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : TheΔAnion Gap/ΔBicarbonate Ratio in Early Lactic Acidosis: Time for Another Delta?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29910040" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139458" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hypokalemic Distal Renal Tubular Acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35721607" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32467307" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low Serum Bicarbonate and CKD Progression in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34444694" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nutritional Approaches for the Management of Metabolic Acidosis in Chronic Kidney Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
